An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results-Reference-Cited by-同舟云学术

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results

Published:2022-09 Issue:9 Volume:28 Page:1293-1296
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Ader Florence

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference4 articles.

1. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19;Ader;Clin Microbiol Infect,2021

2. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19— inal results from the DisCoVeRy trial;Ader,2022

3. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients;Hadjadj;Science,2020

4. Specialized interferon action in COVID-19;Galbraith;Proc Natl Acad Sci USA,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients;New Microbes and New Infections;2023-10

2. Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response;iScience;2023-09

3. Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?;Frontiers in Medicine;2023-05-30